New therapeutic targets for calcific aortic valve stenosis: The lipoprotein(a)-lipoprotein-associated phospholipase A 2 -oxidized phospholipid axis

Journal of the American College of Cardiology

Volumn 63, Issue 5, 2014, Pages 478-480

  Hung, Ming Yow ^a,b,c   Witztum, Joseph L ^c   Tsimikas, Sotirios ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aortic stenosis; calcific aortic valve disease; Lp PLA2; lysophosphatidylcholine; valve interstitial cells

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; EZETIMIBE; LIPOPROTEIN A; OXIDIZED PHOSPHOLIPID; PHOSPHOLIPID; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; DARAPLADIB; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

AORTA VALVE STENOSIS; ARTERY CALCIFICATION; CALCIFIC AORTIC VALVE STENOSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE COURSE; DRUG TARGETING; GENETIC HETEROGENEITY; HUMAN; NOTE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION; VALIDATION PROCESS; AORTA VALVE REPLACEMENT; CALCIFIC AORTA VALVE STENOSIS; CALCIFICATION; CEREBROVASCULAR ACCIDENT; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART INFARCTION; HYPERCHOLESTEROLEMIA; INFLAMMATORY INFILTRATE; LIPID HYDROLYSIS; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT OUTCOME;

AORTIC STENOSIS; CALCIFIC AORTIC VALVE DISEASE; LP-PLA2; LYSOPHOSPHATIDYLCHOLINE; VALVE INTERSTITIAL CELLS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AORTIC VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; FEMALE; GENE EXPRESSION REGULATION; HEART DEFECTS, CONGENITAL; HEART VALVE DISEASES; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEIN(A); MALE; POPULATION SURVEILLANCE; RISK ASSESSMENT; RNA, MESSENGER;

EID: 84893324002     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.08.1639     Document Type: Editorial

References (29)

1. N.M. Rajamannan, F.J. Evans, and E. Aikawa et al. Calcific aortic valve disease: not simply a degenerative process. A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease - 2011 update Circulation 124 2011 1783 1791
2. S. Tsimikas, L.D. Tsironis, and A.D. Tselepis New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease Arterioscler Thromb Vasc Biol 27 2007 2094 2099
3. S. Tsimikas, and J.H. Hall Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies J Am Coll Cardiol 60 2012 716 721
4. G. Thanassoulis, C.Y. Campbell, and D.S. Owens et al. Genetic associations with valvular calcification and aortic stenosis N Engl J Med 368 2013 503 512
5. J.D. Spence, and M.L. Koschinsky Mechanisms of lipoprotein(a) pathogenicity Arterioscler Thromb Vasc Biol 32 2012 1550 1551
6. F. Kronenberg, and G. Utermann Lipoprotein(a): resurrected by genetics J Int Med 273 2013 6 30
7. A. Taleb, J.L. Witztum, and S. Tsimikas Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events Biomarkers Med 5 2011 673 694
8. C. Bergmark, A. Dewan, and A. Orsoni et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma J Lipid Res 49 2008 2230 2239
9. K. Arai, A. Orsoni, and Z. Mallat et al. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia J Lipid Res 53 2012 1670 1678
10. S. Tsimikas, P. Willeit, and J. Willeit et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events J Am Coll Cardiol 60 2012 2218 2229
11. D.M. Stafforini Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2) Cardiovasc Drugs Ther 23 2009 73 83
12. S.A. Karabina, M.C. Elisaf, J. Goudevenos, K.C. Siamopoulos, D. Sideris, and A.D. Tselepis PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro Atherosclerosis 125 1996 121 134
13. C. Blencowe, A. Hermetter, G.M. Kostner, and H.P. Deigner Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein(a) in comparison with low density lipoprotein J Biol Chem 270 1995 31151 31157
14. S. Kiechl, J. Willeit, and M. Mayr et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study Arterioscler Thromb Vasc Biol 27 2007 1788 1795
15. L.S. Rallidis, C.C. Tellis, and J. Lekakis et al. Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up J Am Coll Cardiol 60 2012 2053 2060
16. P.R. Kamstrup, A. Tybjærg-Hansen, and B.G. Nordestgaard Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population J Am Coll Cardiol 63 2014 470 477
17. A. Mahmut, M.-C. Boulanger, and D. El Husseini et al. Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization J Am Coll Cardiol 63 2014 460 469
18. P. Holvoet, J. Donck, and M. Landeloos et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure Thromb Haemost 76 1996 663 669
19. S.G. Tsouli, D.N. Kiortsis, and E.S. Lourida et al. Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia J Lipid Res 47 2006 2208 2214
20. M. Olsson, J. Thyberg, and J. Nilsson Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves Arterioscler Thromb Vasc Biol 19 1999 1218 1222
21. D. Mohty, P. Pibarot, and J.P. Despres et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis Arterioscler Thromb Vasc Biol 28 2008 187 193
22. F. Parhami, A.D. Morrow, and J. Balucan et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients Arterioscler Thromb Vasc Biol 17 1997 680 687
23. N. Mody, F. Parhami, T.A. Sarafian, and L.L. Demer Oxidative stress modulates osteoblastic differentiation of vascular and bone cells Free Rad Biol Med 31 2001 509 519
24. P. Wiesner, M. Tafelmeier, and D. Chittka et al. MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma J Lipid Res 54 2013 1877 1883
25. R.M. Weiss, M. Ohashi, J.D. Miller, S.G. Young, and D.D. Heistad Calcific aortic valve stenosis in old hypercholesterolemic mice Circulation 114 2006 2065 2069
26. J.D. Miller, R.M. Weiss, and K.M. Serrano et al. Lowering plasma cholesterol levels halts progression of aortic valve disease in mice Circulation 119 2009 2693 2701
27. E. Merki, M. Graham, and A. Taleb et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein(a) and lipoprotein(a) in transgenic mice J Am Coll Cardiol 57 2011 1611 1621
28. G. Leibundgut, J.L. Witztum, and S. Tsimikas Oxidation-specific epitopes and immunological responses: translational biotheranostic implications for atherosclerosis Curr Opin Pharmacol 13 2013 168 179
29. P. Libby, A.H. Lichtman, and G.K. Hansson Immune effector mechanisms implicated in atherosclerosis: from mice to humans Immunity 38 2013 1092 1104